Auro Laboratories Ltd.
Auro Laboratories Ltd. - Manufacturer of pharma bulk drugs, active pharma ingredients, bulk active ingredients
Country/Area ：India
Company Email ：hr@aurolabs.com
Industry ：Chemicals MaterialsManufacturing GeneralManufacturingLights & Lighting
Company website ：*****
Company phone ：+91 2266635456
Established ：1989
Company Revenue ：$5,918,000
Number of employees ：71
SIC Code ：28283
NAICS Code ：32325
Main Products ：Potassium IodideTrimethoprim3,4,5 Trimethoxy BenzaldehydeGlibenclamideMetformin HydrochlorideSodium Citrate
Business Info
CIN ：L33125MH1989PLC051910
Registered State ：Maharashtra
Registrar Of Companies ：RoC-Mumbai
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Public
Company Status ：Active
Registered Office Address ：K-56 M I D CTARAPUR INDUSTRIAL AREA, THANE MH IN 401506
Authorized Cap ：70000000.00
Paidup Capital ：62325000.00
Web Summary
Q1: What is the address of Auro Laboratories Ltd.?
A1: The address of Auro Laboratories Ltd. is 9 Shiv Shakti Indl Estate, J. R. Boricha Marg, opp. Kasturba Hospital, Lower Parel (East), Mumbai 400.
Q2: In which industry does Auro Laboratories Ltd. operate?
A2: Although the text does not explicitly state the industry in which Auro Laboratories Ltd. operates, based on the information provided, it appears to be a pharmaceutical or biotechnology company, as indicated by the presence of terms such as "Share Capital" and "Reconciliation of Share" in the content.
Q3: What services does Auro Laboratories Ltd. offer?
A3: The text mentions that Auro Laboratories Ltd. offers various services, including compliance certificate, transfer of shares, and disclosure under regulations. It also provides information on dispute resolution through the Online Dispute Resolution (ODR) platform and the SEBI Complaint Redressal (SCORES) Platform.
Q4: What is the contact information for Auro Laboratories Ltd.?
A4: The text does not provide a direct phone number or email address for Auro Laboratories Ltd., but it mentions that investors can access various forms and documents related to their shares through the ODR portal.
Q5: When was the meeting of the Board of Directors held, and what was the outcome?
A5: According to the text, the meeting of the Board of Directors was held on May 30, 2022. However, the outcome of this meeting is not explicitly stated in the provided content.
Q6: What are some of the regulatory requirements that Auro Laboratories Ltd. needs to comply with?
A6: The text mentions various regulatory requirements that Auro Laboratories Ltd. needs to comply with, including disclosure under regulations (e.g., Regulation 29(2)), compliance certificate, and SEBI Circulars dated March 16, 2023, November 3, 2021, December 14, 2021, January 25, 2022, and September 20, 2023.
Q7: What is the ODR portal for shares related matters?
A7: The text mentions that Auro Laboratories Ltd. has an ODR portal for sharesrelated matters, which can be accessed by investors to resolve disputes and seek information related to their shares.
Q8: When was the Familiarization Programme for Year 20232024 conducted?
A8: According to the text, the Familiarization Programme for Year 20232024 was conducted in the year 2023. However, the exact date is not specified in the provided content.
A1: The address of Auro Laboratories Ltd. is 9 Shiv Shakti Indl Estate, J. R. Boricha Marg, opp. Kasturba Hospital, Lower Parel (East), Mumbai 400.
Q2: In which industry does Auro Laboratories Ltd. operate?
A2: Although the text does not explicitly state the industry in which Auro Laboratories Ltd. operates, based on the information provided, it appears to be a pharmaceutical or biotechnology company, as indicated by the presence of terms such as "Share Capital" and "Reconciliation of Share" in the content.
Q3: What services does Auro Laboratories Ltd. offer?
A3: The text mentions that Auro Laboratories Ltd. offers various services, including compliance certificate, transfer of shares, and disclosure under regulations. It also provides information on dispute resolution through the Online Dispute Resolution (ODR) platform and the SEBI Complaint Redressal (SCORES) Platform.
Q4: What is the contact information for Auro Laboratories Ltd.?
A4: The text does not provide a direct phone number or email address for Auro Laboratories Ltd., but it mentions that investors can access various forms and documents related to their shares through the ODR portal.
Q5: When was the meeting of the Board of Directors held, and what was the outcome?
A5: According to the text, the meeting of the Board of Directors was held on May 30, 2022. However, the outcome of this meeting is not explicitly stated in the provided content.
Q6: What are some of the regulatory requirements that Auro Laboratories Ltd. needs to comply with?
A6: The text mentions various regulatory requirements that Auro Laboratories Ltd. needs to comply with, including disclosure under regulations (e.g., Regulation 29(2)), compliance certificate, and SEBI Circulars dated March 16, 2023, November 3, 2021, December 14, 2021, January 25, 2022, and September 20, 2023.
Q7: What is the ODR portal for shares related matters?
A7: The text mentions that Auro Laboratories Ltd. has an ODR portal for sharesrelated matters, which can be accessed by investors to resolve disputes and seek information related to their shares.
Q8: When was the Familiarization Programme for Year 20232024 conducted?
A8: According to the text, the Familiarization Programme for Year 20232024 was conducted in the year 2023. However, the exact date is not specified in the provided content.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
